相似文献
1
Editorial: Molecular Characterization of Thyroid Lesions in the Era of "Next-Generation" Techniques.
Front Endocrinol (Lausanne). 2022 Jun 29;13:955185. doi: 10.3389/fendo.2022.955185. eCollection 2022.
2
Thoughtful Utilization of Molecular Testing in Refining Thyroid Nodule Risk Assessment: Do Not Throw Out the Baby.
Thyroid. 2020 Apr;30(4):474-475. doi: 10.1089/thy.2020.0148.
3
Unraveling Hürthle cell lesions of the thyroid using molecular findings.
Cancer Cytopathol. 2022 Jun;130(6):405-406. doi: 10.1002/cncy.22567. Epub 2022 Mar 14.
4
What is the role of molecular markers in the management of "indeterminate" thyroid nodules?
Cancer Cytopathol. 2013 May;121(5):223-4. doi: 10.1002/cncy.21289.
5
[Next generation sequencing].
Rev Med Brux. 2016;37(5):436-438.
6
A novel nonsense EIF1AX mutation identified in a thyroid nodule histologically diagnosed as oncocytic carcinoma.
Endocrine. 2018 Nov;62(2):492-495. doi: 10.1007/s12020-018-1611-7. Epub 2018 Apr 26.
7
Use of Molecular Diagnostic Tests in Thyroid Nodules with Hürthle Cell-Dominant Cytology.
Thyroid. 2020 Sep;30(9):1390-1392. doi: 10.1089/thy.2020.0021. Epub 2020 May 4.
8
Utility of molecular testing in the management of thyroid nodules - a clinical perspective.
Cytopathology. 2015 Oct;26(5):284-7. doi: 10.1111/cyt.12281.
9
The Role of Molecular Testing for the Indeterminate Thyroid FNA.
Genes (Basel). 2019 Sep 23;10(10):736. doi: 10.3390/genes10100736.
10
Genetic markers differentiating follicular thyroid carcinoma from benign lesions.
Mol Cell Endocrinol. 2010 May 28;321(1):77-85. doi: 10.1016/j.mce.2009.11.008. Epub 2009 Nov 20.
本文引用的文献
1
Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases.
Histopathology. 2022 Jan;80(2):322-337. doi: 10.1111/his.14550. Epub 2021 Oct 7.
2
Next generation sequencing in cytology.
Cytopathology. 2021 Sep;32(5):588-595. doi: 10.1111/cyt.12974. Epub 2021 Apr 1.
3
Moving towards a local testing solution for undetermined thyroid fine-needle aspirates: validation of a novel custom DNA-based NGS panel.
J Clin Pathol. 2022 Jul;75(7):465-471. doi: 10.1136/jclinpath-2021-207429. Epub 2021 Mar 31.
4
Telomerase Reverse Transcriptase (TERT) Regulation in Thyroid Cancer: A Review.
Front Endocrinol (Lausanne). 2020 Jul 31;11:485. doi: 10.3389/fendo.2020.00485. eCollection 2020.
5
Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
Cancer Cytopathol. 2021 Jan;129(1):33-42. doi: 10.1002/cncy.22331. Epub 2020 Jul 22.
6
Molecular Diagnostic of Solid Tumor Using a Next Generation Sequencing Custom-Designed Multi-Gene Panel.
Diagnostics (Basel). 2020 Apr 23;10(4):250. doi: 10.3390/diagnostics10040250.
7
Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy.
Expert Rev Mol Diagn. 2019 Dec;19(12):1079-1088. doi: 10.1080/14737159.2020.1688144. Epub 2019 Nov 10.
8
Clinical validation of the ThyroSeq v3 genomic classifier in thyroid nodules with indeterminate FNA cytology.
Cancer Cytopathol. 2019 Apr;127(4):225-230. doi: 10.1002/cncy.22112. Epub 2019 Feb 27.
9
Genome-wide profiling identifies the THYT1 signature as a distinctive feature of widely metastatic Papillary Thyroid Carcinomas.
Oncotarget. 2017 Dec 1;9(2):1813-1825. doi: 10.18632/oncotarget.22805. eCollection 2018 Jan 5.
10
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
N Engl J Med. 2017 Dec 21;377(25):2500-2501. doi: 10.1056/NEJMc1713444.
Zotero 插件